Laurus Labs Limited (LAURUSLABS) Q2 FY27 Financial Results: PAT ₹368 Cr & Revenue ₹2,026 Cr(2 announcements)
| Metric | Value |
|---|---|
| Revenue | ₹2,026 Cr |
| Net Profit (PAT) | ₹368 Cr |
Laurus Labs reported Q1 FY27 revenue of ₹2,026 crores, up 29% YoY, driven by strong CDMO growth and expanded profitability. Gross margins rose to 62.7% and EBITDA margins reached 31.8%, reflecting improved operational leverage. Net profit surged 126% to ₹368 crores with diluted EPS at [amount not verified]The company highlighted strategic progress including ADC in-licensing and land acquisition, while maintaining CAPEX at 19% of sales to fund future capacity expansion in peptides, gene therapy, and ADCs.
| Metric | Value |
|---|---|
| Revenue | ₹2,026 Cr |
| Net Profit (PAT) | ₹368 Cr |
Laurus Labs reported Q1 FY27 revenue of ₹2,026 crores, up 29% YoY, driven by strong CDMO growth and Affordable Medicines momentum. Gross margins expanded to 62.7% (+3.3 pts), EBITDA rose 66% to ₹644 crores with 31.8% margin, and Net Profit surged 126% to ₹368 crores. CAPEX stood at ₹394 crores (19% of revenue), with 85% allocated to Growth CAPEX. The company highlighted continued investment in manufacturing expansion, including new sites and capacity additions across API, Peptides, and Gene Therapy, while maintaining SBTi ESG targets.
About Laurus Labs Limited (LAURUSLABS)
Healthcare · Pharmaceuticals · Listed on NSE
📡 Get AI alerts when LAURUSLABS files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track LAURUSLABS — Free💡 Ask AI about this filing
📊 More LAURUSLABS filings
- 🔴 Announcement — 31 August 2026 Laurus Labs announced it will attend the Antique Pharma Investor Day in Hyderabad on September 7, 20...
- Announcement — 12 August 2026 Laurus Labs announced its participation in the Motilal Oswal Annual Global Investor Conference on Au...
- Announcement — 10 August 2026 Laurus Labs Limited announced that NSE Sustainability Ratings and Analytics independently assigned a...
- Announcement — 30 July 2026 Laurus Labs reported Q1 FY27 revenue of INR2,026 crores, up 29% YoY, with EBITDA margin expanding to...
- 🔴 Corporate Action — 27 July 2026 Laurus Labs allotted 62,635 equity shares of Rs.2 each to employees exercising stock options across ...
🔥 Also filed on 24 July 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when LAURUSLABS files new disclosures
Track LAURUSLABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track LAURUSLABS — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd